Target type: biologicalprocess
The process in which a relatively unspecialized cell acquires specialized features of a lens fiber cell, any of the elongated, tightly packed cells that make up the bulk of the mature lens in the camera-type eye. The cytoplasm of a lens fiber cell is devoid of most intracellular organelles including the cell nucleus, and contains primarily crystallins, a group of water-soluble proteins expressed in vary large quantities. [GOC:mah, PMID:7693735]
Lens fiber cell differentiation is a complex and tightly regulated process that involves the coordinated expression of numerous genes and the interplay of various signaling pathways. It begins with the commitment of epithelial cells in the lens vesicle to a lens fiber cell fate. This commitment is driven by the expression of transcription factors such as Pax6, Sox1, and Maf. These factors activate a cascade of downstream genes that control the differentiation process.
As lens fiber cells differentiate, they undergo a series of dramatic changes, including:
* **Elongation and loss of organelles**: Lens fiber cells elongate significantly, extending from the lens epithelium to the lens center. They also lose most of their organelles, including their nuclei, mitochondria, and endoplasmic reticulum. This loss of organelles is essential for maintaining the transparency of the lens.
* **Expression of crystallins**: Lens fiber cells express high levels of crystallins, which are proteins that are responsible for the refractive index of the lens. Crystallins are organized into a highly ordered array that contributes to the lens's ability to focus light.
* **Formation of cell junctions**: Lens fiber cells form specialized cell junctions, called gap junctions, which allow for the passage of ions and small molecules between cells. This communication is essential for maintaining lens homeostasis.
The differentiation of lens fiber cells is a continuous process throughout life. New fiber cells are continuously produced from the lens epithelium and migrate towards the lens center, replacing older, more differentiated cells. This process ensures the maintenance of lens transparency and refractive power.
Disruptions in lens fiber cell differentiation can lead to a variety of eye diseases, including cataracts and other lens opacities. Understanding the molecular mechanisms underlying lens fiber cell differentiation is therefore essential for developing new therapies for these debilitating conditions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cystine/glutamate transporter | A cystine/glutamate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UPY5] | Homo sapiens (human) |
Lysine-specific demethylase 5B | A lysine-specific demethylase 5B that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UGL1] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
alpha-ketoglutaric acid | 2-oxoglutaric acid : An oxo dicarboxylic acid that consists of glutaric acid bearing an oxo substituent at position 2. It is an intermediate metabolite in Krebs cycle. | oxo dicarboxylic acid | fundamental metabolite |
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
sulfapyridine | sulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position. Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases. | pyridines; substituted aniline; sulfonamide; sulfonamide antibiotic | antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
cysteine | cysteine; cysteine zwitterion; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite | |
2,4-pyridinedicarboxylic acid | lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4. | pyridinedicarboxylic acid | |
quisqualic acid | Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis. | non-proteinogenic alpha-amino acid | |
serine o-sulfate | L-serine O-sulfate : A non-proteinogenic L-alpha-amino acid that is the O-sulfo derivative of L-serine. serine O-sulfate: RN given refers to (L)-isomer | L-serine derivative; non-proteinogenic L-alpha-amino acid; O-sulfoamino acid | |
homocysteic acid | homocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid. homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd L-homocysteic acid : A homocysteic acid with L-configuration. | homocysteic acid | NMDA receptor agonist |
oxalylglycine | N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes. oxalylglycine: structure given in first source | amino dicarboxylic acid; N-acylglycine | EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor |
susalimod | susalimod: analogue of sulphasalazine, was designed for use in the treatment of rheumatoid arthritis | ||
erastin | erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer. erastin: an antineoplastic agent; structure in first source | aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide | antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor |
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid | organonitrogen heterocyclic compound |